Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 29Triple Negative Breast Neoplasms 13Prostatic Neoplasms 13Ovarian Neoplasms 12Neoplasms 12Neoplasm Metastasis 9Fallopian Tube Neoplasms 6Leukemia, Myeloid, Acute 5Small Cell Lung Carcinoma 4Pancreatic Neoplasms 4Endometrial Neoplasms 4Colorectal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Advanced Solid Tumors 4Carcinoma, Renal Cell 3Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Sarcoma, Ewing 2Recurrence 2Neuroectodermal Tumors, Primitive, Peripheral 2Lung Neoplasms 2Carcinoma, Ovarian Epithelial 2mCRPC 1Wilms Tumor 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Triple Negative Metastatic Breast Cancer 1Thrombocythemia, Essential 1Solid Tumor 1Sarcoma 1

Interventions

Specimen Handling 2talazoparib 1Taxes 1Paclitaxel 1Immunoglobulin G 1Doxorubicin 1Disulfides 1Cyclophosphamide 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Adenocarcinoma × talazoparib × Clear all
NCT02282345 2022-07-06

Talazoparib Before Standard Therapy in Treating Patients With Invasive, BRCA-Mutated Breast Cancer

M.D. Anderson Cancer Center

Phase 2 Completed
36 enrolled 14 charts
Breast

Breast Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡